KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Revenue (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Revenue for 16 consecutive years, with $1.7 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 180.06% year-over-year to $1.7 billion, compared with a TTM value of $3.7 billion through Dec 2025, up 65.19%, and an annual FY2025 reading of $3.7 billion, up 65.19% over the prior year.
  • Revenue was $1.7 billion for Q4 2025 at Alnylam Pharmaceuticals, up from $1.2 billion in the prior quarter.
  • Across five years, Revenue topped out at $1.7 billion in Q4 2025 and bottomed at $30.0 million in Q1 2025.
  • Average Revenue over 5 years is $483.6 million, with a median of $327.2 million recorded in 2022.
  • The sharpest move saw Revenue skyrocketed 183.96% in 2023, then crashed 93.93% in 2025.
  • Year by year, Revenue stood at $258.5 million in 2021, then rose by 29.59% to $335.0 million in 2022, then surged by 31.25% to $439.7 million in 2023, then soared by 34.9% to $593.2 million in 2024, then soared by 180.06% to $1.7 billion in 2025.
  • Business Quant data shows Revenue for ALNY at $1.7 billion in Q4 2025, $1.2 billion in Q3 2025, and $773.7 million in Q2 2025.